About Us

In 2022, CHOSA Oncology was founded by the very team that had pioneered LiPlaCis. Backed by decades of experience in oncology and biotechnology, we are committed to advancing cancer treatment. Our merger with RhoVac AB in the same year enabled us to expand our reach and impact globally.

A scientist wearing blue gloves preparing a syringe with a pharmaceutical substance in a laboratory setting.

Starting with LiPlaCis®

Our story started with the development of LiPlaCis®, a breakthrough in cancer treatment that emerged from a collaboration between the Danish Technical University and the University of Copenhagen. Designed to enhance the efficacy of cisplatin while reducing its toxicity, LiPlaCis represents a leap forward in personalized cancer care

Close-up of a touchscreen display showing samples of purple ink or pigment arranged in rectangular wells, with white plastic framing and some handwritten labels.

Innovation with DRP®

Our Drug Response Predictor (DRP®) is a breakthrough technology that identifies patients who will respond best to platin-based treatments, enabling a truly personalized approach to cancer care. By tailoring treatment to each patient's biology, we can improve outcomes and advance precision medicine. This approach also allows doctors to avoid giving cisplatin to non-responders, sparing them side effects and ensuring they can access potentially more effective treatments without delay.

Exterior of the BioInnovation Institute building with large glass windows and a sign displaying 'BI' and 'BioInnovation Institute'.

Our Global Presence

While our main office is located in Medicon Village in Lund, Sweden, we are proud to be part of the thriving biotech ecosystem at the BioInnovation Institute (BII) in Copenhagen, Denmark. This dual presence allows us to harness the best of Scandinavian innovation and research in oncology.

We continue transforming cancer care through smarter, more targeted treatments. We remain dedicated to improving outcomes for patients worldwide and believe that by combining cutting-edge science with compassion, we can make a profound difference.

Looking to the Future

Take a look for yourself…

Take a look at our CEO, Peter Buhl Jensen, explaining CHOSA’s role in the cancer-treatment market, in context with ESMO 2024.

Meet the Team

Our team is dedicated to advancing cancer care with compassion, innovation, and expertise. Each member of our team brings specialized knowledge and a shared commitment to improving patient outcomes and supporting our partners in oncology.

CHOSA well established management team, both sitting and standing
  • Title slide for drug response predictor presentation with CHOSA logo and a purple topographic design.
  • Slide titled "The synergy of platinum and PD-(L)1" discussing the market impact and relevance of combining PD-(L)1 therapies with platinum-based treatments for PD-(L)1, highlighting their market value, effectiveness in certain patients, and potential benefits for patients.
  • Summary slide with four purple boxes titled 'Challenge in cancer care,' 'DRP® technology,' 'A growing competitive market,' and 'Patient-centered innovation,' containing bullet points about cancer treatment challenges, medication identification technology, market growth, and healthcare innovations.
  • A presentation slide explaining the DRP® algorithm for predicting patient responses to cisplatin treatment, highlighting its basis in multigene mRNA analysis, patented genes, and evidence-based oncology results.
  • Diagram showing three steps of how the DRP® works: Analyse with a microscope, Score on a computer, Treatment by a healthcare professional.
  • Bar graph showing the impact of DRP on PCR rates in lung cancer patients. It compares treatment methods like Cisplatin, Nivolumab, Nivolumab with Cisplatin, DRP-A, DRP-B, and DRP-C, with purple bars for percentage of patients treated and dark purple bars for PCR rates.
  • Slide titled 'DRP® Validation & Studies' detailing clinical studies for cisplatin in breast and lung cancer, and CHOSA's investment in Key Opinion Leader validation, with summary points and a chart.
  • A presentation slide outlining the clinical benefits of using DRP, including non-invasive testing, low investment, simple and fast process, and being platinum-specific but not cancer-specific, with the CHOSA logo in the bottom right corner.
  • Two women, one with cancer in a head covering, hugging outdoors with a blue sky background, beside a purple and white graphic with text about core values related to patient-centered healthcare and innovative treatments, including mention of cisplatin and PD-(L)1 market.
  • Bar chart showing estimated sales of PD-L1 inhibitors in 2023 with sales in billion USD, comparing sales with and without a platinum-based drug. Total sales estimated at 49.5 billion USD, with a breakdown for different medications.
  • A presentation slide titled 'Precision Medicine with DRP.' It explains that DRP predicts patient responses to cisplatin, leading to increased response rates, faster cure, higher approval rates, smaller trials, better outcomes for oncologists, and increased likelihood of guidelines and reimbursement. CHOSA logo is in the bottom right corner.
  • Bar chart showing that increased PCR rates lead to higher market share in a medical treatment market. The chart compares different treatments - Cisplatin + PD-1, DRP-A, DRP-B, DRP-C - with percentages for PCR rate, patients in PD-1 Cisplatin market, and theoretical market share of Cisplatin/PD-1. A red arrow indicates an upward trend from lower to higher market share as PCR rate increases.
  • Slide titled "Driving Precision Medicine to New Markets" with purple text on a white background. It discusses expanding the use of combination therapy in medical markets, including multiple cancer types, patient subgroups, and emerging markets. The slide features a purple globe icon and the CHOSA logo with the tagline 'Intelligent Oncology.'
  • Slide titled 'Differentiate from Competition' with subtitle 'Building strong brand reputation whilst extending market exclusivity and increasing sales'; four sections titled 'Enhanced Performance,' 'Extend Patent Life,' 'Unique Offering,' and 'Creates a Premium Product'; and the company name 'Chosa' at the bottom right.
  • Purple background with white text quoting about healthcare innovation and patient welfare, with decorative line patterns in the corners.
  • A thank you slide with the word 'THANKS!' in large purple letters, contact information for Peter Buhl Jensen, and a website link for chosaoncology.com. The background features purple contour lines resembling topographical maps.
Learn about DRP®